Sana Biotechnology, Inc. (SANA) SEC Filings & Earnings Calls

Early-stage data; regulatory and manufacturing risks remain.

“Phase 1/2 trial not yet started; IND filing targeted for 2026.”

Going concern risk

“Management has determined that our present capital resources may not be sufficient to fund our planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to our ability to continue as a going concern.” · word for word

No revenue from product sales

“Since our inception, we have not generated any revenue from product sales or any other sources, and we have incurred significant operating losses.” · word for word

Dependence on future financing

“Our ability to continue as a going concern will depend on, among other things, our ability to obtain additional funding and appropriately manage the amount of cash used to fund our operations.” · word for word

Dilution risk from equity financing

“If we raise additional funds through the issuance of equity or convertible debt securities, existing stockholders’ ownership interests will be diluted.” · word for word

Tariff impact on R&D costs

“Recent and potential future developments in international trade, including tariffs imposed on imports from other countries, could cause unanticipated increases in our research and development costs, primarily through increased CDMO costs and costs of our laboratory and manufacturing supplies.” · word for word

Pre-revenue biotech with significant cash burn; clinical trial risk.

“Net loss and accumulated deficit; cash runway only into mid-2027.”

Equity offering dilutes existing shareholders.

“sold an aggregate of 21,607,878 shares of its common stock”

Going concern risk

“Management has determined that our present capital resources may not be sufficient to fund our planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to our ability to continue as a going concern.” · word for word

Dilution risk from ATM facility

“In March 2026, we entered into the Sales Agreement... pursuant to which we may offer and sell up to $150.0 million of shares of our common stock from time to time under the ATM facility.” · word for word

Pre-revenue biotechnology company with significant cash burn; runway only into 2027

“expected cash runway into 2027” · word for word

Clinical-stage programs face inherent development and regulatory risks

“We are working to file our IND and begin a Phase 1 trial later this year for SC451” · word for word

Pre-commercial Stage Risk

“Sana is a pre-commercial biotechnology company with no approved products, relying on R&D progress and capital markets for funding.”

Cash Burn Risk

“Net income of -$270M in FY2026 indicates significant cash burn, requiring continued access to capital.”

Equity offering dilutes existing shareholders; potential additional dilution if Mayo Clinic exercises option.

“sell to Mayo Clinic... 7,507,507 shares... additional 7,507,507 shares”

Significant shareholder dilution from ATM offering

“up to $150.0 million of securities”

Cash runway only into late 2026; need for additional capital

“expected cash runway into late 2026” · word for word

Going concern risk

“There is substantial doubt as to our ability to continue as a going concern.” · word for word

Novel technology risk

“Our ex vivo and in vivo cell engineering platforms are based on novel technologies that are unproven and may not result in approvable or marketable products.” · word for word

Funding risk

“We will require additional funding to finance our operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce, or eliminate some or all of our product development programs or commercialization efforts.” · word for word

Pipeline concentration risk: focus on two early-stage programs with no approved products; suspension of allogeneic CAR T programs reduces diversification.

“Sana announced it will prioritize future development activity for SC451 and SG293. The company has suspended development of its two allogeneic cell therapy CAR T programs – SC291 and SC262.” · word for word

Cash runway limited to late 2026, requiring further financing or milestone success.

“expected cash runway into late 2026” · word for word

Cash runway less than one year

“we believe that our existing cash, cash equivalents, and marketable securities ... will be sufficient to meet our working capital and capital expenditure needs for at least one year from the filing of this Quarterly Report. However, we will need to raise additional financing in the future to fund our operations.” · word for word

No revenue from product sales

“Since our inception, we have not generated any revenue from product sales or any other sources, and we have incurred significant operating losses.” · word for word

Tariff impact on R&D costs

“recent and potential future developments in international trade, including tariffs imposed on imports from other countries, could cause unanticipated increases in our research and development costs, primarily through increased CDMO costs and costs of our laboratory supplies” · word for word